Skip to main content
. 2022 Oct 21;14(20):5172. doi: 10.3390/cancers14205172

Figure 2.

Figure 2

Cumulative hazard plot of gastric cancer development according to the duration of medication. H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor.